

<b>REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL</b>	<i>Application No.:</i> <b>10/533,863</b> <i>Filing Date:</i> <b>May 5, 2005</b> <i>First Named Inventor:</i> <b>Christoph GEIBERGER</b> <i>Group Art Unit:</i> <b>3723</b> <i>Examiner:</i> <b>Laura Guidotti</b> <i>Attorney Docket No.:</i> <b>C70518</b>
Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	
<b>Confirmation No. 9661</b> <b>Electronically Filed on: November 13, 2008</b>	
This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. <b>NOTE:</b> 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20,2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.	

<b>1. <u>Submission required under 37 C.F.R. § 1.114</u></b>	
a.	<input type="checkbox"/> Previously submitted <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____. (Any unentered amendment(s) referred to above will be entered)</li> <li>ii. <input type="checkbox"/> Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____.</li> <li>iii. <input type="checkbox"/> Other _____</li> </ul>
b.	<input checked="" type="checkbox"/> <b><u>Enclosed</u></b> <ul style="list-style-type: none"> <li>i. <input checked="" type="checkbox"/> Amendment/Reply <u>7</u> pages</li> <li>ii. <input type="checkbox"/> Affidavit(s)/Declaration(s) _____ pages</li> <li>iii. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS) <u>1</u> page</li> <li>iv. <input checked="" type="checkbox"/> Form PTO 1449 <u>1</u> pgs. &amp; <u>1</u> references attached</li> <li>v. <input type="checkbox"/> Other _____</li> </ul>
<b>2. <u>Miscellaneous</u></b>	
a.	<input type="checkbox"/> Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(I) required)
b.	<input type="checkbox"/> Other _____
<b>3. <u>FEES</u></b> The RCE fee under 37 C.F.R. § 1.117(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.	
a.	<input checked="" type="checkbox"/> The Director is hereby authorized to charge the following fees or credit any overpayments, to <b>Deposit Account No. <u>19-2570</u></b> .
<input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))	
i.	<input checked="" type="checkbox"/> RCE fee required under 37 C.F.R. § 1.17(e). <span style="float: right;"><b>\$810.00</b></span>
ii.	<input checked="" type="checkbox"/> ( 1 ) Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) <span style="float: right;"><b>\$130.00</b></span>
iii.	<input type="checkbox"/> Additional Fees
iv.	<input checked="" type="checkbox"/> <b>Total Fee to be charged to Deposit Account <u>19-2570</u></b> <span style="float: right;"><b><u>\$940.00</u></b></span>

<b>CORRESPONDENCE ADDRESS:</b>		<b>RESPECTFULLY SUBMITTED,</b>
<i>Address</i>	GLAXOSMITHKLINE Corporate Intellectual Property – UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939	
<i>Telephone</i>	(610) 270-5044 <i>Facsimile</i> (610) 270-5090	<i>Signature:</i> NAME : <b>Nora Stein-Fernandez</b>  Registration No. <b>36,689</b>

**Customer No. 20462**